| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,190 | 1,310 | 21.12. |
| FDA Approves Expanded Use Of Johnson & Johnson's TRUFILL N-BCA For Subdural Hematoma | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson MedTech, the medical technology arm of Johnson & Johnson (J&J) on Thursday said the U.S. Food and Drug Administration (FDA) has approved an expanded... ► Artikel lesen |
| Johnson & Johnson MedTech: Johnson & Johnson Receives FDA Approval for TRUFILL n-BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma | - TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH)... ► Artikel lesen |
| FDA Approves Johnson & Johnson's RYBREVANT FASPRO, First Subcutaneous Therapy For EGFR-Mutated NSCLC | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first and only... ► Artikel lesen |
| CTP signs lease with Procter & Gamble for 37,000 sqm flagship facility in Prague | Regulatory News:
CTP, Europe's largest listed owner, developer, and operator of logistics and industrial real estate by gross leasable area, has signed a major lease agreement with global consumer... ► Artikel lesen |
| Eastman Chemical, AstraZeneca, Kraft Heinz und P&G mit OMP Supply Chain Awards ausgezeichnet | MIAMI, FLORIDA / ACCESS Newswire /
16. Dezember 2025 / AstraZeneca, Eastman, Kraft Heinz und P&G wurden für ihren herausragenden Beitrag auf der jüngsten OMP-Konferenz ausgezeichnet. Die vier... ► Artikel lesen |
| Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards | MIAMI, FLORIDA / ACCESS Newswire / December 16, 2025 / AstraZeneca, Eastman, Kraft Heinz, and P&G have been recognized for their outstanding contribution at the recent OMP Conference. The four industry... ► Artikel lesen |
| BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen |
| BB Biotech - Turning milestones into momentum | BB Biotech (BION) delivered strong Q325 results, underpinned by its focus on innovative biotech companies with differentiated clinical pipelines and promising long-term potential. NAV increased 24.0%... ► Artikel lesen |
| Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Oct-2025 / 12:15 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen |